Literature DB >> 28861674

[Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].

I Kötter1, N Stübiger2, C Deuter3.   

Abstract

There are many interfaces between ophthalmologists and rheumatologists. On the one hand ophthalmologists face the question if an inflammation of the eye is caused by systemic inflammatory rheumatic diseases and on the other hand rheumatologists have to consider that ocular manifestations are relatively common in some inflammatory rheumatic diseases. Furthermore, these ocular manifestations may influence therapeutic decisions of the rheumatologist. This article summarizes which ocular inflammations can be associated with rheumatoid arthritis, connective tissue diseases and vasculitides. The description of acute anterior uveitis in spondyloarthritis and in juvenile idiopathic arthritis is omitted in this article but will be dealt with elsewhere in this issue.

Entities:  

Keywords:  Ocular inflammation; Ophthalmologist; Rheumatologist; Systemic inflammatory rheumatic diseases; Uveitis

Mesh:

Substances:

Year:  2017        PMID: 28861674     DOI: 10.1007/s00393-017-0372-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  22 in total

Review 1.  Therapy insight: scleritis and its relationship to systemic autoimmune disease.

Authors:  Justine R Smith; Friederike Mackensen; James T Rosenbaum
Journal:  Nat Clin Pract Rheumatol       Date:  2007-04

2.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 3.  Ocular manifestations in systemic lupus erythematosus.

Authors:  Sukhum Silpa-archa; Joan J Lee; C Stephen Foster
Journal:  Br J Ophthalmol       Date:  2015-04-22       Impact factor: 4.638

Review 4.  Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature.

Authors:  Pierre-Raphaël Rothschild; Christian Pagnoux; Raphaele Seror; Antoine P Brézin; Emmanuelle Delair; Loïc Guillevin
Journal:  Semin Arthritis Rheum       Date:  2012-12-24       Impact factor: 5.532

Review 5.  Ophthalmologic manifestations of rheumatic diseases.

Authors:  F Hamideh; P E Prete
Journal:  Semin Arthritis Rheum       Date:  2001-02       Impact factor: 5.532

6.  Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.

Authors:  Christoph M E Deuter; Manfred Zierhut; Antje Möhle; Reinhard Vonthein; Nicole Stöbiger; Ina Kötter
Journal:  Arthritis Rheum       Date:  2010-09

7.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 8.  Giant cell arteritis: an updated review.

Authors:  Aki Kawasaki; Valerie Purvin
Journal:  Acta Ophthalmol       Date:  2008-10-07       Impact factor: 3.761

9.  Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies.

Authors:  Ammapati Paul Pandian Vignesh; Renuka Srinivasan
Journal:  Clin Ophthalmol       Date:  2015-02-25

10.  Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: A cross-sectional analysis.

Authors:  Alexander Chen; Hung-Ta Chen; Yih-Hsiou Hwang; Yi-Tsun Chen; Ching-Hsi Hsiao; Hung-Chi Chen
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more
  1 in total

1.  Study of Factors Influencing Dry Eye in Rheumatoid Arthritis.

Authors:  Weifang Ma; Guoliang Wang; Xiaofeng Li; Huping Wu; Zuguo Liu; Nuo Dong; Cheng Li
Journal:  J Ophthalmol       Date:  2020-08-08       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.